-
Mashup Score: 1Source: link.springer.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
In addition to female breast and ovarian cancers, BRCA1 and BRCA2 PVs are associated with increased risks of male breast, pancreatic, stomach, and prostate (only BRCA2 PVs) cancers, but not with the risks of other previously suggested cancers. The estimated age-specific risks wi …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
SCI leader Esther John & others found that in addition to female breast & ovarian cancers, #BRCA1 & #BRCA2 PVs are associated with increased risks of male breast, pancreatic, stomach, & prostate (only BRCA2PVs) cancers, but not other suggested cancers. https://t.co/FqZbvvVCRH https://t.co/KmFJ29XRz8
-
-
Mashup Score: 0
Lurbinectedin, a selective inhibitor of oncogenic transcription, has shown preclinical antitumor activity against homologous recombination repair-deficient models and preliminary clinical activity in BRCA1/2 breast cancer.
Source: Esmo OpenCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline #BRCA1/2 metastatic breast cancer #mBC: results from a #phaseII basket study @OncoAlert @myESMO @cczielinski @PaoloBossi6 https://t.co/dC0PuxFXpY https://t.co/DMwVUJVekX
-
-
Mashup Score: 9Mayo Clinic's Fergus Couch, Ph.D., awarded Basser Global Prize for BRCA Research - Mayo Clinic News Network - 2 year(s) ago
ROCHESTER, Minn. — The Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania has awarded Mayo Clinic’s Fergus Couch, Ph.D., with the 10th annual Basser Global Prize. This highly distinguished award recognizes a leading scientist who has advanced research related to BRCA1 and BRCA2 genes. People with mutations in these […]
Source: Mayo Clinic News NetworkCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Congratulations to Dr. Fergus Couch, who was awarded the highly distinguished @BasserBRCA Global Prize for his work contributing to #BRCA1 and #BRCA2 research. @MayoCancerCare https://t.co/2d1sB1ce1l
-
-
Mashup Score: 5Study Seeks to Prevent Cancer and Extend Quality of Life for Women at Increased Genetic Risk of Ovarian Cancer - 2 year(s) ago
Study Seeks to Prevent Cancer and Extend Quality of Life for Women at Increased Genetic Risk of Ovarian Cancer
Source: Division of Cancer PreventionCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Researchers in gynecologic oncology have begun testing a promising surgery for premenopausal women at high genetic risk for #OvarianCancer that could avoid early menopause while still preventing the tumor. https://t.co/0rnwpIjEsM @NRGonc @FacingOurRisk #BRCA1 https://t.co/jPLclZGsSk
-
-
Mashup Score: 1Study confirms BRCA1 and BRCA2 linked to seven cancers - 2 year(s) ago
Some associations are stronger than others with biliary tract, esophageal, and gastric cancers rising to the top.
Source: www.mdedge.comCategories: Latest Headlines, OBGYNTweet-
A large case-control study finds the range of cancer types associated with pathogenic variants in #BRCA1 and #BRCA2 is broader than previously determined. https://t.co/2RVI5E2aMH https://t.co/qxflOeMKth
-
-
Mashup Score: 4
The Institute of Cancer Research, London, strongly welcomes the news that olaparib has been recommended by the European Medicines Agency (EMA) to treat people with high-risk, early-stage breast cancer who have inherited faults in their BRCA1 or BRCA2 genes.
Source: www.icr.ac.ukCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
💊📣NEWS: Olaparib has been recommended by @EMA_News to treat people with high-risk early-stage #BreastCancer with inherited faults in their #BRCA1 or #BRCA2 genes. This means patients will be a step closer to accessing the treatment. Read more👇 https://t.co/xBISzRiobW https://t.co/YZbE1rDNjT
-
-
Mashup Score: 2Mutations differ across younger and older breast cancer patients - 2 year(s) ago
Women younger than 40 years of age with advanced breast cancer often suffer from more aggressive disease and worse prognoses than their older counterparts. Knowing which types of genetic mutations these patients tend to have could inform treatment strategies and improve outcomes. In a new study, Yale Cancer Center researchers investigated the genomic alterations of patients with breast cancer,…
Source: EurekAlert!Categories: Healthcare Professionals, Latest HeadlinesTweet-
Mutations differ across younger and older #breastcancer patients https://t.co/Fcn48QDErp #BCSM #MedTwitter #PM101 "Patients in the younger age groups had higher rates of #BRCA1 mutations and lower rates of #CDH1 and #PIK3CA mutations than did older patients."
-
-
Mashup Score: 2Points to Consider Regarding Risk-Reducing Mastectomy in High-, Moderate-, and Low-Penetrance Gene Carriers - Annals of Surgical Oncology - 2 year(s) ago
Risk-reducing mastectomy is considered a safe and effective surgical procedure in high-risk individuals with BRCA1/2 germline mutations. Multigene panels identify women with alterations in breast cancer susceptibility genes other than BRCA1/2. International guidelines classify these genes as high-, moderate-, and low-penetrance based on their associated relative risk for breast cancer….
Source: SpringerLinkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
AHEAD OF PRINT: Points to Consider Regarding #RiskReducingMastectomy in High-, Moderate-, and Low-Penetrance #GeneCarriers. #BRCA1/2 https://t.co/8v80FqzzVS @McMastersKelly @SocSurgOnc https://t.co/JZnTW5m41O
-
-
Mashup Score: 5Germline Pathogenic Variants in BRCA1 and BRCA2: Malignancies Beyond Female Breast and Ovarian Cancers - 2 year(s) ago
© 2022 by American Society of Clinical OncologySUPPORTSupported by the Breast Cancer Research Foundation (NY, to E.L.L.).Financial support: Ephrat Levy-LahadCollection and assembly of data: All authorsData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable…
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🧐 #JCO #UnderstandingThePathway: Germline Pathogenic Variants in #BRCA1 and #BRCA2: Malignancies Beyond Female #BreastCancer and #OvarianCancer https://t.co/iuSwiH3WxB #gyncsm #BCSM #pancsm #PCSM https://t.co/rGBhQjGUCT
-
DECEMBER ISSUE: Points to Consider Regarding De-Escalation Surgery in #HighRiskBreastCancer. #BRCA1/2 https://t.co/xShH7jXEbA @McMastersKelly @SocSurgOnc https://t.co/wcMqV3JYj2